* Acumen Pharmaceuticals Inc reported a quarterly adjusted loss of 50 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -24 cents. The mean expectation of six analysts for the quarter was for a loss of 36 cents per share. Wall Street expected results to range from -46 cents to -25 cents per share.

* Reported revenue was zero​; analysts expected zero.

* Acumen Pharmaceuticals Inc's reported EPS for the quarter was a loss of 50 cents​.

* The company reported a quarterly loss of $29.77 million.

* Acumen Pharmaceuticals Inc shares had risen by 29.8% this quarter and lost 16.1% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had fallen by about 6.7% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Acumen Pharmaceuticals Inc is $11.00 This summary was machine generated from LSEG data November 12 at 03:37 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.36 -0.50 Missed

Jun. 30 2024 -0.28 -0.34 Missed

Mar. 31 2024 -0.26 -0.25 Beat

Dec. 31 2023 -0.26 -0.28 Missed